Multispecific
antibody
platform
Our Multiclonics® therapeutics are full-length human IgG bispecific (Biclonics®) and trispecific (Triclonics®) antibodies that bind to multiple targets, and are manufactured with advantageous features for anti-cancer effects against the complex mechanisms that drive cancer. Multiclonics® are capable of being developed with industry standard processes and have been observed in preclinical studies to have similar features as conventional monoclonal antibodies, such as long half-life and low immunogenicity. Biclonics® can also be conjugated with a range of linkers and payloads to generate antibody-drug conjugates (ADClonics®) capable of binding two different targets with the potential for improved binding selectivity, internalization and cancer cell killing activity.
Established
clinical
pipeline
Our therapeutic candidates engage cancer antigens and harness the power of the immune system to kill tumor cells in unique and powerful ways by utilizing our proprietary technology platform and deep expertise in oncology. We are currently developing a broad pipeline of wholly owned and licensed Biclonics® drug candidates in the clinic with compelling target combinations and unique mechanisms of action.
Lead
asset
petosemtamab
Our lead cancer drug candidate is petosemtamab, a Biclonics® antibody targeting EGFR and LGR5. Petosemtamab has shown encouraging single agent clinical activity in previously treated, 2L+ recurrent or metastatic (r/m) head and neck cancer, and in combination with pembrolizumab in first line (1L) PD-L1+ r/m head and neck cancer, with phase three trials enrolling in both indications. An evaluation of petosemtamab monotherapy in 3L+ metastatic colorectal cancer (mCRC) and in combination with standard chemotherapy in 1L and 2L mCRC is ongoing.